UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of

1934

Date of Report (Date of earliest event reported): November 15, 2007

PFIZER INC.

(Exact

name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of

incorporation)

1-3619

(Commission File Number)

13-5315170

(I.R.S. Employer Identification

No.)

235 East 42nd Street, New York, New

York 10017

(Address of

principal executive offices) (zip code)

(212) 573-2323

(Registrant's telephone

number)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the obligation of the registrant

under any of the following provisions:

[ ] Written communication

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule

14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule

13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other

Events

Exhibit 100 to this Current Report on Form 8-K

contains documents formatted in XBRL (eXtensible Business Reporting Language)

with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter

ended September 30, 2007, filed with the Securities and Exchange Commission

(SEC) on November 5, 2007. The information formatted in XBRL includes the (i)

Condensed Consolidated Statements of Income for the three months and nine months

ended September 30, 2007, and October 1, 2006, (ii) Condensed Consolidated

Balance Sheets as of September 30, 2007, and at December 31, 2006, and (iii)

Condensed Consolidated Statements of Cash Flows for the nine months ended September

30, 2007 and October 1, 2006.

Users of this data are advised pursuant to Rule

401 of Regulation S-T that the financial information contained in the

XBRL-Related Documents is unaudited and these are not the official financial

statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these

XBRL formatted documents is solely for the purpose of participation in the SEC's

voluntary XBRL pilot program to test the related format and technology and, as a

result, investors should continue to rely on the official filed version of the

furnished documents and not rely on the information in this Current Report on

Form 8-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of

Regulation S-T, the information in this Current Report on Form 8-K, including

Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18

of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or

otherwise subject to the liability of that section, and shall not be

incorporated by reference into any registration statement or other document

filed under the Securities Act of 1933, as amended, or the Exchange Act, except

as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and

Exhibits.

(d)

Exhibits

The following exhibits are furnished

herewith:

Exhibit

Number

Exhibit

Description

100

The following financial statements from

Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended September

30, 2007, filed on November 5, 2007, formatted in XBRL (extensible Business

Reporting Language): (i) the Condensed Consolidated Statements of Income

for the three months and nine ended September 30, 2007, and October 1,

2006, (ii) the Condensed Consolidated Balance Sheets as of September 30,

2007, and December 31, 2006, and (iii) the Condensed Consolidated Statements

of Cash Flows for the nine months ended September 30, 2007 and October

1, 2006.

SIGNATURE

Under the requirements of the Securities

Exchange Act of 1934, the registrant has caused this report to be signed

on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M.

Foran

Margaret M. Foran

Dated: November 15, 2007

Title: Senior Vice

President-Corporate Governance

Associate General Counsel and Corporate

Secretary

EXHIBIT INDEX

Exhibit No.

Description

EX-100.INS

XBRL Instance Document

EX-100.SCH

XBRL Taxonomy Extension Schema

Document

EX-100.SCH.1

XBRL Schema Supplement Document

EX-100.CAL

XBRL Taxonomy Extension Calculation

Linkbase Document

EX-100.LAB

XBRL Taxonomy Extension Label Linkbase

Document

EX-100.PRE

XBRL Taxonomy Extension Presentation

Linkbase Document